Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

NCT06430827 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Carcinoma

Interventions

DRUG: irinotecan hydrochloride liposome injection
DRUG: Capecitabine

Sponsor

Ba Yi

Collaborators

[object Object]